Development and validation of an early diagnosis model for severe mycoplasma pneumonia in children based on interpretable machine learning

基于可解释机器学习的儿童重症支原体肺炎早期诊断模型的开发与验证

阅读:1

Abstract

BACKGROUND: Pneumonia is a major threat to the health of children, especially those under the age of five. Mycoplasma  pneumoniae infection is a core cause of pediatric pneumonia, and the incidence of severe mycoplasma pneumoniae pneumonia (SMPP) has increased in recent years. Therefore, there is an urgent need to establish an early warning model for SMPP to improve the prognosis of pediatric pneumonia. METHODS: The study comprised 597 SMPP patients aged between 1 month and 18 years. Clinical data were selected through Lasso regression analysis, followed by the application of eight machine learning algorithms to develop early warning model. The accuracy of the model was assessed using validation and prospective cohort. To facilitate clinical assessment, the study simplified the indicators and constructed visualized simplified model. The clinical applicability of the model was evaluated by DCA and CIC curve. RESULTS: After variable selection, eight machine learning models were developed using age, sex and 21 serum indicators identified as predictive factors for SMPP. A Light Gradient Boosting Machine (LightGBM) model demonstrated strong performance, achieving AUC of 0.92 for prospective validation. The SHAP analysis was utilized to screen advantageous variables, which contains of serum S100A8/A9, tracheal computed tomography (CT), retinol-binding protein(RBP), platelet larger cell ratio(P-LCR) and CD4+CD25+Treg cell counts, for constructing a simplified model (SCRPT) to improve clinical applicability. The SCRPT diagnostic model exhibited favorable diagnostic efficacy (AUC > 0.8). Additionally, the study found that S100A8/A9 outperformed clinical inflammatory markers can also differentiate the severity of MPP. CONCLUSIONS: The SCRPT model consisting of five dominant variables (S100A8/A9, CT, RBP, PLCR and Treg cell) screened based on eight machine learning is expected to be a tool for early diagnosis of SMPP. S100A8/A9 can also be used as a biomarker for validity differentiation of SMPP when medical conditions are limited.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。